These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety. Gurka MK; Collins SP; Slack R; Tse G; Charabaty A; Ley L; Berzcel L; Lei S; Suy S; Haddad N; Jha R; Johnson CD; Jackson P; Marshall JL; Pishvaian MJ Radiat Oncol; 2013 Mar; 8():44. PubMed ID: 23452509 [TBL] [Abstract][Full Text] [Related]
8. Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma. Lin C; Verma V; Ly QP; Lazenby A; Sasson A; Schwarz JK; Meza JL; Are C; Li S; Wang S; Hahn SM; Grem JL Radiother Oncol; 2019 Mar; 132():55-62. PubMed ID: 30825970 [TBL] [Abstract][Full Text] [Related]
9. Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer. Rajagopalan MS; Heron DE; Wegner RE; Zeh HJ; Bahary N; Krasinskas AM; Lembersky B; Brand R; Moser AJ; Quinn AE; Burton SA Radiat Oncol; 2013 Oct; 8():254. PubMed ID: 24175982 [TBL] [Abstract][Full Text] [Related]
10. Adjuvant stereotactic body radiotherapy for resected pancreatic adenocarcinoma with close or positive margins. Rwigema JC; Heron DE; Parikh SD; Zeh HJ; Moser JA; Bahary N; Ashby K; Burton SA J Gastrointest Cancer; 2012 Mar; 43(1):70-6. PubMed ID: 20809393 [TBL] [Abstract][Full Text] [Related]
11. Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative radiation therapy in borderline resectable or locally advanced pancreatic adenocarcinoma. Quan K; Sutera P; Xu K; Bernard ME; Burton SA; Wegner RE; Zeh H; Bahary N; Stoller R; Heron DE Pract Radiat Oncol; 2018; 8(2):95-106. PubMed ID: 29291966 [TBL] [Abstract][Full Text] [Related]
12. Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study. Comito T; Cozzi L; Clerici E; Franzese C; Tozzi A; Iftode C; Navarria P; D'Agostino G; Rimassa L; Carnaghi C; Personeni N; Tronconi MC; De Rose F; Franceschini D; Ascolese AM; Fogliata A; Tomatis S; Santoro A; Zerbi A; Scorsetti M Technol Cancer Res Treat; 2017 Jun; 16(3):295-301. PubMed ID: 27311310 [TBL] [Abstract][Full Text] [Related]
13. Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer. Wild AT; Herman JM; Dholakia AS; Moningi S; Lu Y; Rosati LM; Hacker-Prietz A; Assadi RK; Saeed AM; Pawlik TM; Jaffee EM; Laheru DA; Tran PT; Weiss MJ; Wolfgang CL; Ford E; Grossman SA; Ye X; Ellsworth SG Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):571-9. PubMed ID: 26867885 [TBL] [Abstract][Full Text] [Related]
14. Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Polistina F; Costantin G; Casamassima F; Francescon P; Guglielmi R; Panizzoni G; Febbraro A; Ambrosino G Ann Surg Oncol; 2010 Aug; 17(8):2092-101. PubMed ID: 20224860 [TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes and prognostic factors of stereotactic body radiation therapy combined with gemcitabine plus capecitabine for locally advanced unresectable pancreatic cancer. Shen ZT; Zhou H; Li AM; Ji XQ; Jiang CC; Yuan X; Li B; Zhu XX; Huang GC J Cancer Res Clin Oncol; 2020 Feb; 146(2):417-428. PubMed ID: 31667573 [TBL] [Abstract][Full Text] [Related]
16. Quantification of renal function following stereotactic body radiotherapy for pancreatic cancer: secondary dosimetric analysis of a prospective clinical trial. Verma V; Bhirud AR; Denniston KA; Bennion NR; Lin C Radiat Oncol; 2017 Apr; 12(1):71. PubMed ID: 28449702 [TBL] [Abstract][Full Text] [Related]
17. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer. Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605 [TBL] [Abstract][Full Text] [Related]
18. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V; Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442 [TBL] [Abstract][Full Text] [Related]
19. Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer. Goldstein D; Van Hazel G; Walpole E; Underhill C; Kotasek D; Michael M; Shapiro J; Davies T; Reece W; Harvey J; Spry N Br J Cancer; 2007 Aug; 97(4):464-71. PubMed ID: 17653074 [TBL] [Abstract][Full Text] [Related]
20. A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer. Martenson JA; Vigliotti AP; Pitot HC; Geeraerts LH; Sargent DJ; Haddock MG; Ghosh C; Keppen MD; Fitch TR; Goldberg RM Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1305-10. PubMed ID: 12654442 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]